Applied Molecular Cuts Its Workforce By 40%, Pauses Early-Stage Research Programs Applied Molecular Transport Inc (NASDAQ:AMTI) will prioritize the advancement of AMT-101 into late-stage clinical development. It is preparing for the end of Phase 2 meetings with the FDA to advance AMT-101 to Phase 3 in chronic pouchitis. Applied Molecular is evaluating the next steps for AMT-126, which recently demonstrated safety and tolerability in… Benzinga · May 18, 2022
Applied Molecular: Q4 Earnings Insights Applied Molecular (NASDAQ:AMTI) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Benzinga · Feb 24, 2022